8 August 2022
Alkemy Capital Investments Plc
The following amendment has been made to the 'Oversubscribed Placing to raise £1.2m and Directors Purchase of Shares' announcement released on 4 August 2022 at 7:00am
The amount of new ordinary shares admitted to trading should have been 1,199,999 and not 1,200,000. Therefore the total amount raised from the placing is £1,199,999 and the companies enlarged issued share capital is 7,199,998 Ordinary Shares.
The full amended text is shown below:
4 August 2022
Alkemy Capital Investments Plc
Oversubscribed Placing to raise £1.2m and Directors Purchase of Shares
Alkemy Capital Investments plc ("Alkemy") (LSE: ALK) and its wholly owned subsidiary Tees Valley Lithium Ltd ("TVL") are pleased to announce the following corporate update.
Highlights:
· £1.2m new funds, before expenses, raised by Alkemy from new and existing shareholders through a placing of 1,199,999 new ordinary shares at £1 per share
· £178,000 of these new shares are being subscribed for by Directors, showing strong support
Fundraise and Director Purchase of Shares
Alkemy is pleased to announce that it has raised £1.2m in an oversubscribed placing of 1,199,999 new ordinary shares at a placing price of £1 per share.
This includes cash subscriptions of £178,000 from the directors, including Paul Atherley (£78,000), Sam Quinn (£75,000) and Helen Pein (£25,000).
The net proceeds will be used to further fastrack the development of TVL's lithium hydroxide processing faclility in Teesside, UK and for general working capital purposes.
Following the placing, the directors will have the following shareholdings in the Company:
| Number of Shares | % of enlarged capital |
Paul Atherley (Chairman) | 3,078,000 | 42.75% |
Sam Quinn (Director) | 325,000 | 4.51% |
Helen Pein (Director) | 25,000 | 0.35% |
An application will be made for 1,199,999 Ordinary Shares to be admitted to the official list (Standard Segment) and to trading on the Main Market of the London Stock Exchange ("Admission") and Admission is expected to occur at 8.00 a.m. on 9 August 2022 ("Admission").
In accordance with the FCA's Disclosure Guidance and Transparency Rules, the Company confirms that following Admission, the Company's enlarged issued ordinary share capital will comprise 7,199,998 Ordinary Shares each with a right to vote and with no shares held in treasury . Therefore, following Admission, the above figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the Company, under the FCA's Disclosure Guidance and Transparency Rules.
Grant of Share Options
The Company also announces the proposed grant of 590,000 share options at £1 per share, for a period of 5 years, to further align Directors and senior management with shareholders. A further announcement will be made once the options have been granted.
Alkemy and TVL Director, Sam Quinn, commented:
"We are grateful to all the existing and new shareholders who have contributed to this fundraise, which will help enable the further fast-tracked development of TVL's lithium hydroxide processing facility in Teesside, UK. Funds will be used to commence and advance FEED and to complete the planning process. We appreciate the ongoing support from all stakeholders and look forward to a successful year ahead as we move to establish the UK's first major independent and sustainable lithium hydroxide producer at the Wilton International Chemicals Park in Teesside, UK".
Further information
For further information, please visit the Company's website: www.alkemycapital.co.uk or www.teesvalleylithium.co.uk
-Ends-
Alkemy Capital Investments Plc Sam Quinn | Tel: 0207 317 0636 |
Buchanan Bobby Morse/Abigail Gilchrist | Tel: 0207 466 5000 TVL@buchanan.uk.com |
VSA Capital Limited Andrew Monk (corporate broking) Andrew Raca (corporate finance) | Tel: 0203 005 5000 |
Shard Capital Partners LLP Damon Heath
Isabella Pierre |
Tel: 0207 186 9952 Tel: 0207 186 9927 |
NOTES TO EDITORS
Alkemy is seeking to develop, construct and operate the world's leading independent and sustainable lithium hydroxide production facility.
Alkemy, through its wholly-owned subsidiary Tees Valley Lithium, has secured a 9.6ha brownfields site at the Wilton International Chemicals Park located in Teesside, a major UK Freeport.
Alkemy has completed a Class 4 Feasibility Study for its proposed lithium hydroxide facility which will process feedstock imported from various sources to produce 96,000 tonnes of premium, low-carbon lithium hydroxide annually, representing around 15% of Europe's projected demand.
Forward Looking Statements
This news release contains forward‐looking information. The statements are based on reasonable assumptions and expectations of management and Alkemy provides no assurance that actual events will meet management's expectations. In certain cases, forward‐looking information may be identified by such terms as "anticipates", "believes", "could", "estimates", "expects", "may", "shall", "will", or "would". Although Alkemy believes the expectations expressed in such forward‐looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those projected. Mining exploration and development is an inherently risky business. In addition, factors that could cause actual events to differ materially from the forward-looking information stated herein include any factors which affect decisions to pursue mineral exploration on the relevant property and the ultimate exercise of option rights, which may include changes in market conditions, changes in metal prices, general economic and political conditions, environmental risks, and community and non-governmental actions. Such factors will also affect whether Alkemy will ultimately receive the benefits anticipated pursuant to relevant agreements. This list is not exhaustive of the factors that may affect any of the forward‐looking statements. These and other factors should be considered carefully and readers should not place undue reliance on forward-looking information.
The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation in relation to the transaction listed above is set out below.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Paul Atherley | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chairman | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Alkemy Capital Investments PLC | |||
b)
| LEI
| 213800NW5GVIRMXSRL48 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares
| |||
| | ||||
Identification code | GB00BMD6C023 | ||||
| | ||||
b)
| Nature of the transaction
| Subscription of shares | |||
c)
| Price(s) and volume(s) | | | | |
| | Price(s) | Volume(s) | | |
| | £1.00 | 150,000 | | |
| | | | | |
d)
| Aggregated information | | |||
| | ||||
- Aggregated volume | 150,000 | ||||
| | ||||
- Price | £150,000 | ||||
| | ||||
e)
| Date of the transaction
| 03/08/2022 | |||
f)
| Place of the transaction
| Outside a trading venue |
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Sam Quinn | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Non-Executive Director | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Alkemy Capital Investments PLC | |||
b)
| LEI
| 213800NW5GVIRMXSRL48 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares
| |||
| | ||||
Identification code | GB00BMD6C023 | ||||
| | ||||
b)
| Nature of the transaction
| Subscription of shares | |||
c)
| Price(s) and volume(s) | | | | |
| | Price(s) | Volume(s) | | |
| | £1.00 | 120,000 | | |
| | | | | |
d)
| Aggregated information | | |||
| | ||||
- Aggregated volume | 120,000 | ||||
| | ||||
- Price | £120,000 | ||||
| | ||||
e)
| Date of the transaction
| 03/08/2022 | |||
f)
| Place of the transaction
| Outside a trading venue |
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Helen Pein | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Non-Executove Director | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Alkemy Capital Investments PLC | |||
b)
| LEI
| 213800NW5GVIRMXSRL48 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares
| |||
| | ||||
Identification code | GB00BMD6C023 | ||||
| | ||||
b)
| Nature of the transaction
| Subscription of shares | |||
c)
| Price(s) and volume(s) | | | | |
| | Price(s) | Volume(s) | | |
| | £1.00 | 25,000 | | |
| | | | | |
d)
| Aggregated information | | |||
| | ||||
- Aggregated volume | 25,000 | ||||
| | ||||
- Price | £25,000 | ||||
| | ||||
e)
| Date of the transaction
| 03/08/2022 | |||
f)
| Place of the transaction
| Outside a trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.